Company / R&D per Share
NeoGenomics Laboratories, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.29
FY2025
5-year range
$0.18 / $0.29
FY2021-FY2025
Trend
+17.7%
vs FY2024
Sector context
#96 of 108
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s r&d per share of $0.29 is lower than 89% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $0.03 in FY2018 to $0.29 in FY2025.
Based on SEC 10-K filings.
0.29 in FY2025 with a 5-year CAGR of +31.5%.
Improved from $0.22 to $0.29 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- +31.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 108This company $0.29 Sector average $2.07
▼
-86.0% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 17.7% year-over-year.
- Ranks #96 out of 108 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.29 | +17.7% |
| FY2024 | $0.25 | +13.1% |
| FY2023 | $0.22 | -10.9% |
| FY2022 | $0.24 | +33.9% |
| FY2021 | $0.18 | +147.7% |
| FY2020 | $0.07 | -10.1% |
| FY2019 | $0.08 | +149.9% |
| FY2018 | $0.03 | -29.2% |
| FY2017 | $0.05 | -24.5% |
| FY2016 | $0.06 | -12.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026